Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

Details 詳細情報について

• CRID

  1360574093547189504

• DOI

  10.1007/s00520-005-0914-4

• ISSN

  14337339

  09414355

• Web Site

  http://link.springer.com/content/pdf/10.1007/s00520-005-0914-4.pdf

  http://link.springer.com/article/10.1007/s00520-005-0914-4/fulltext.html

  http://link.springer.com/content/pdf/10.1007/s00520-005-0914-4

• Data Source

  • Crossref